drugset
drugset / Trial / NCT05607446

To Evaluate the Efficacy and Safety of TQC3564 Tablets in the Treatment of Persistent Allergic Rhinitis

NCT05607446 ↗

Phase 1 Terminated 12 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
RandomizedCrossoverQuadruple-blindTreatment

Summary

A clinical study to evaluate the efficacy and safety of tqc3564 tablets in the treatment of persistent allergic rhinitis. A total of 24 patients will be enrolled.

Timeline

Start
2022-09-14
Primary completion
2023-05-09
Completion
2023-12-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Montelukast Other / unclassified — Oral
Subject TQC3564 Unknown — Oral

Indications

allergic rhinitis